SCHEMBL10192177

SCHEMBL10192177

CC(C)(C)NCCN1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.56
PRMT6 Q96LA8 1/20 0.56
PRMT8 Q9NR22 1/20 0.56
CACNA1H O95180 1/20 0.43
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CA12 O43570 3/20 0.39
CA1 P00915 3/20 0.39
CA2 P00918 3/20 0.39
CA9 Q16790 3/20 0.39
HRH3 Q9Y5N1 1/20 0.39
NPC1 O15118 1/20 0.38
DPP7 Q9UHL4 1/20 0.37
SIGMAR1 Q99720 1/20 0.36
ALDH1A1 P00352 3/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7745180 0.98 CARM1 (0.54) CARM1PRMT6PRMT8CACNA1HMEN1
SCHEMBL13137785 0.98 CARM1 (0.54) CARM1PRMT6PRMT8CACNA1HMEN1
SCHEMBL19961023 0.95 CARM1 (0.50) CARM1PRMT6PRMT8CACNA1HMEN1
SCHEMBL23922127 0.90 CACNA1H (0.49) CARM1PRMT6PRMT8CACNA1HMEN1
SCHEMBL10259141 0.86 CARM1 (0.46) CARM1PRMT6PRMT8HRH3SIGMAR1
SCHEMBL12257623 0.85 HRH3 (0.50) CARM1PRMT6PRMT8HRH3SIGMAR1
SCHEMBL13762258 0.85 HRH3 (0.50) CARM1PRMT6PRMT8HRH3SIGMAR1
SCHEMBL20314580 0.84 CACNA1H (0.43) CARM1PRMT6PRMT8CACNA1HMEN1
SCHEMBL7745202 0.84 CACNA1H (0.45) CARM1PRMT6PRMT8CACNA1HSIGMAR1
SCHEMBL5833206 0.83 HRH3 (0.54) CARM1PRMT6PRMT8HRH3SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11833122-B2 Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases CALGENT BIOTECHNOLOGY CO., LTD. (TW) 2023-12-05 US disclosed
US-20230285573-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-09-14 US disclosed
US-20230285573-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-09-14 US disclosed
US-20230123334-A1 AMINO LIPID COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shenzhen Shenxin Biotechnology Co., Ltd. (CN) 2023-04-20 US disclosed
US-20230050819-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-02-16 US disclosed
US-11505562-B2 Process for the generation of metal-containing films BASF SE (DE) 2022-11-22 US disclosed
US-20220204452-A1 ANTIMALARIAL COMPOUNDS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2022-06-30 US disclosed
US-11220486-B2 Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY (US) 2022-01-11 US disclosed
US-20210284629-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2021-09-16 US disclosed
US-20210283265-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2021-09-16 US disclosed
US-20080262008-A1 useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph WYETH (US) 2008-10-23 US disclosed
US-20080194545-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE TRIUS THERAPEUTICS (US) 2008-08-14 US disclosed
US-20080096884-A1 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors GLAXO GROUP LIMITED (GB) 2008-04-24 US disclosed
US-20080096887-A1 cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor SERENEX, INC. 2008-04-24 US disclosed
US-7358370-B2 Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide SERENEX, INC. (US) 2008-04-15 US disclosed
US-7326703-B2 (1,10B-Dihydro-2-(aminocarbonyl-phenyl)-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors TIBOTEC PHARMACEUTICALS LTD (IL) 2008-02-05 US disclosed
US-20070248624-A1 (1,10B-Dihydro-2-(Aminocarbonyl-Phenyl)-5h-Pyrazolo[1,5-C][1,3]Benzoxazin-5-Yl)Phenyl Methanone Derivatives as Hiv Viral Replication Inhibitors JANSSEN SCIENCES IRELAND UC (IE) 2007-10-25 US disclosed
US-20070248624-A1 (1,10B-Dihydro-2-(Aminocarbonyl-Phenyl)-5h-Pyrazolo[1,5-C][1,3]Benzoxazin-5-Yl)Phenyl Methanone Derivatives as Hiv Viral Replication Inhibitors JANSSEN SCIENCES IRELAND UC (IE) 2007-10-25 US disclosed
US-20070244140-A1 Anilino-pyrimidine phenyl and benzothiophene analogs WYETH (US) 2007-10-18 US disclosed
US-20070191363-A1 Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues NEUROGEN CORPORATION (US) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11505562-B2 Process for the generation of metal-containing films NR2E1, NR0B2, NR2C2 CARM1 493/4885PRMT6 260/4885PRMT8 166/4885
US-11220486-B2 Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof ACP1, PTPRCAP, PTPA CARM1 2970/4885PRMT6 1628/4885PRMT8 1015/4885
US-20070191363-A1 Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues AHR, HCAR2, HCAR1 CARM1 3087/4885PRMT6 3140/4885PRMT8 3267/4885
US-20080194545-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE ABCB11, FPR1, C5 CARM1 4827/4885PRMT6 3570/4885PRMT8 4658/4885
US-20080096884-A1 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors PDE4A, PDE4B, PDE3B CARM1 1005/4885PRMT6 681/4885PRMT8 834/4885
US-20230285573-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE NEDD4, CBL, UBQLN2 CARM1 2527/4885PRMT6 1241/4885PRMT8 1211/4885
US-20210283265-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE NEDD4, CBL, UBQLN2 CARM1 2527/4885PRMT6 1241/4885PRMT8 1211/4885
US-20230050819-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE CYFIP2, TPX2, ATXN2 CARM1 1812/4885PRMT6 829/4885PRMT8 715/4885
US-20070244140-A1 Anilino-pyrimidine phenyl and benzothiophene analogs HPRT1, APRT, NUDT1 CARM1 3503/4885PRMT6 744/4885PRMT8 3050/4885
US-20080096887-A1 cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor HSP90AA1, HSP90AB1, HSPA4 CARM1 3057/4885PRMT6 3792/4885PRMT8 4598/4885
US-20070248624-A1 (1,10B-Dihydro-2-(Aminocarbonyl-Phenyl)-5h-Pyrazolo[1,5-C][1,3]Benzoxazin-5-Yl)Phenyl Methanone Derivatives as Hiv Viral Replication Inhibitors POLRMT, MAVS, DHX15 CARM1 3959/4885PRMT6 2594/4885PRMT8 2953/4885
US-11833122-B2 Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases KEAP1, GOT2, COL1A1 CARM1 1397/4885PRMT6 567/4885PRMT8 1443/4885
US-20220204452-A1 ANTIMALARIAL COMPOUNDS H1-3, FPR3, NHERF1 CARM1 790/4885PRMT6 1657/4885PRMT8 1356/4885
US-20080262008-A1 useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph CSNK1A1, PRKX, PRKACA CARM1 3884/4885PRMT6 1998/4885PRMT8 2778/4885
US-20230123334-A1 AMINO LIPID COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF CETP, PLIN1, NOTUM CARM1 2798/4885PRMT6 790/4885PRMT8 320/4885
US-20210284629-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE NEDD4, UBQLN2, UBTF CARM1 2396/4885PRMT6 1582/4885PRMT8 1224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.